Spravato Logo.png

A New Day Begins With Spravato

Clouds in Sky

FDA Approved

IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT (AD) FOR TREATMENT-RESISTANT DEPRESSION (TRD) IN ADULTS¹

The first and only NMDA receptor antagonist approved for TRD in adults

SPRAVATO™ hypothesized mechanism of action

NasalSpray_Effects.png

BASELINE PSYCHIATRIC PATIENT CHARACTERISTICS

Spravato_Comparison.png
Studied in more than 1700 adult patients with treatment-resistant depression

BASELINE PSYCHIATRIC PATIENT CHARACTERISTICS

1  2

Spravato_BaselinePsychiatric.png

References:

1.SPRAVATO™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. March 2019.

2.Data on file. Janssen Pharmaceuticals, Inc. Titusville, NJ.

Indication:
SPRAVATO™ (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant (AD), for the treatment of treatment-resistant depression (TRD) in adults.​

SPRAVATO™ is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO™ as an anesthetic agent have not been established.

For more information on SPRAVATO treatment give us a call at 855.4CHARAK

Use The Link Below To Learn More About Important Safety Information...